Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: A meta-analysis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Chen, Min Bin ^a   Zhu, Ya Qun ^b   Xu, Jun Ying ^c   Wang, Li Qiang ^a   Liu, Chao Ying ^c   Ji, Zhang Yi ^a   Lu, Pei Hua ^c  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; GENE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; META ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMATIC REVIEW; TP53 GENE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; PUBLICATION BIAS; RISK FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863102966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039655     Document Type: Article

References (35)

1. Tewari M, Krishnamurthy A, Shukla HS, (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 17: 301-311.
2. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, et al. (2011) TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 12: 527-539.
3. Vousden KH, Prives C, (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
4. Lowe SW, Ruley HE, Jacks T, Housman DE, (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
5. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
6. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F, (2003) Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 14: 428-432.
7. Zhou B, Yang DQ, Xie F, (2008) Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J (Engl) 121: 387-391.
8. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, et al. (2007) HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 7: 36.
9. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, et al. (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6: 50-56.
10. Sanchez-Munoz A, Duenas-Garcia R, Jaen-Morago A, Carrasco E, Chacon I, et al. (2010) Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine +/- trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 33: 432-437.
11. Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, et al. (2003) Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 39: 438-446.
12. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, et al. (2009) Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 26: 344-349.
13. Martin-Richard M, Munoz M, Albanell J, Colomo L, Bellet M, et al. (2004) Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66: 388-394.
14. Pakos EE, Kyzas PA, Ioannidis JP, (2004) Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res 10: 6208-6214.
15. Oshima K, Naoi Y, Kishi K, Nakamura Y, Iwamoto T, et al. (2011) Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. Cancer Lett 307: 149-157.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A, (1981) Reporting results of cancer treatment. Cancer 47: 207-214.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
18. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, et al. (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600.
19. Schneider J, Gonzalez-Roces S, Pollan M, Lucas R, Tejerina A, et al. (2001) Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3: 183-191.
20. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, et al. (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512.
21. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, et al. (2003) TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9: 5582-5588.
22. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, et al. (2003) Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 14: 406-413.
23. Deissler H, Kafka A, Schuster E, Sauer G, Kreienberg R, et al. (2004) Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep 11: 1281-1286.
24. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, et al. (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 40: 342-351.
25. Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, et al. (2005) HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103: 2252-2260.
26. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, et al. (2005) High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11: 8425-8430.
27. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, et al. (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7: 203.
28. Lee J, Im YH, Lee SH, Cho EY, Choi YL, et al. (2008) Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 61: 569-577.
29. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, et al. (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4: e90.
30. Shekhar MP, Biernat LA, Pernick N, Tait L, Abrams J, et al. (2010) Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. Med Oncol 27: 466-473.
31. Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, et al. (2011) Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol 67: 911-917.
32. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, et al. (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28: 1145-1153.
33. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, et al. (2011) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat.
34. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, et al. (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496-1506.
35. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667.